STAT Investigation Exposes Exploitative 'Three-Parent IVF' Tourism for Older Women
A STAT investigation reveals that 'three-parent IVF' (MRT), a technique originally designed to prevent fatal mitochondrial diseases, is being commercially marketed to older women in the U.S. and Europe despite lacking scientific evidence for efficacy. An Illinois-based facilitator, International Fertility Group (IFG), connects patients with clinics in Albania, Ukraine, and elsewhere, charging tens of thousands of dollars for a procedure that experts say fails for most women over 40. While IFG claims high success rates, independent data suggests these figures are misleading or unsubstantiated. The practice remains illegal in the U.S. due to congressional bans, leading to a shadow industry of medical tourism. Critics warn that patients are being financially exploited and subjected to unproven medical experiments, while proponents argue it offers a last resort for those with advanced maternal age.
Key points
- IFG, based in Northbrook, Illinois, acts as a middleman connecting patients in the U.S. and Europe with foreign clinics offering MRT, charging over $30,000 per cycle.
- MRT involves transferring nuclear DNA from a patient’s egg into a donor egg that has had its nucleus removed, retaining the donor’s mitochondria to potentially boost energy for embryo development.
- The procedure is illegal in the U.S. since 2015, when Congress blocked the FDA from approving clinical trials involving modified embryos, but is permitted in countries with lax regulations like Albania and Ukraine.
- IFG claims a 50% pregnancy success rate for MRT, but provides no peer-reviewed data to support this; independent experts and former patients report high failure rates for women over 40.
- Embryologist Pavlo Mazur, a pioneer in the field, found that MRT does not fix age-related infertility because the issue is often damaged nuclear DNA, not mitochondrial energy, and has since distanced himself from commercial applications.
- IFG recently paused new patient intake and removed MRT mentions from its website following STAT inquiries, citing a need for a 'comprehensive review' and cautious expansion.
Background
MRT was initially developed to prevent mitochondrial diseases, with limited use approved in the U.K. for specific cases. The commercialization of MRT for general infertility, particularly for older women, emerged after regulatory bans in the U.S. created a vacuum for unregulated international clinics. Previous archive coverage on medical ethics and regulatory gaps highlights broader concerns about unregulated medical tourism and the exploitation of vulnerable patients seeking reproductive solutions.
Why it matters
This story highlights the ethical and financial risks of unregulated medical tourism, where desperate patients may be exploited by unproven treatments. It underscores the dangers of bypassing regulatory frameworks, potentially leading to long-term health consequences for children born through MRT and financial ruin for families. The lack of transparency and peer-reviewed data raises serious questions about the integrity of the global fertility industry.
What to watch
IFG has suspended its MRT promotion pending a review, but the broader industry may continue to operate in jurisdictions with minimal oversight. Experts call for rigorous clinical trials to determine the safety and efficacy of MRT for infertility, while regulatory bodies may need to address the gaps in international medical tourism. Patients are advised to seek evidence-based treatments and be wary of unproven claims.
Want the full story? Read the original reporting
Read on STAT